The Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) recently released a report exploring the potential for pharmacogenomics (PGx) to advance the development of diagnostic, therapeutic, and preventive strategies to improve the safety, effectiveness, and quality of health care; identify opportunities and critical barriers in need of the Federal Government’s attention; and make 35 policy recommendations aimed at enhancing the development and integration of PGx applications.
PGx has drawn great attention in the United States and abroad for its potential to improve drug research and development (R&D), health care delivery, and ultimately, patient health. SACGHS was established in 2002 to deliberate and provide advice to the Department of Health and Human Services (HHS) on the broad range of policy issues raised by the development and use of genetic and genomic technologies. In writing and distributing this report, it is SACGHS’s intent to provide policy-relevant information about PGx to inform the decisions of clinicians, policymakers, and other stakeholders. More information about SACGHS is available at http://www4.od.nih.gov/oba/SACGHS.htm.
0 Comments